TP-II: Efficacy of de-escalated therapies in patients with triple positive breast cancer
22. Januar 2024 News
The TP-II study is a multicenter, randomized phase II trial comparing 2 neoadjuvant de-escalation treatments in HR-positive/ERBB2-positive EBC that palleos healthcare conducts as sponsor. Due to outstanding recruitment, study treatment of the last patient was completed earlier than originally planned in July 2020. In the TP-II trial, an excellent pCR rate after 12 weeks of Read full article...
